Cargando…

Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients

Cytochrome P450 (CYP) 3A5 polymorphism influences tacrolimus metabolism, but its effect on the drug pharmacokinetics in liver transplant recipients switched to once-daily extended-release formulation remains unknown. The aim of this study is to analyze the effect of CYP3A5 polymorphism on liver func...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jong Man, Ryu, Je Ho, Lee, Kwang-Woong, Hong, Suk Kyun, Yang, Kwangho, Choi, Gyu-Seong, Kim, Young-Ae, Lee, Ju-Yeun, Yi, Nam-Joon, Kwon, Choon Hyuck David, Chu, Chong Woo, Suh, Kyung-Suk, Joh, Jae-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563461/ https://www.ncbi.nlm.nih.gov/pubmed/32911703 http://dx.doi.org/10.3390/jcm9092897

Ejemplares similares

Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients
por: Suh, Suk-Won, et al.
Publicado: (2016)

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
por: Kim, Jong Man, et al.
Publicado: (2021)

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

Safety and Efficacy of Conversion from Twice-Daily Tacrolimus to Once-Daily Tacrolimus One Month after Transplantation: Randomized Controlled Trial in Adult Renal Transplantation
por: Oh, Chang-Kwon, et al.
Publicado: (2014)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients
por: Kim, Jong Man, et al.
Publicado: (2014)

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
por: Gaber, A. Osama, et al.
Publicado: (2013)

Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study
por: Lapeyraque, Anne-Laure, et al.
Publicado: (2014)

Generic Tacrolimus (Tacrobell(®)) Shows Comparable Outcomes to Brand-Name Tacrolimus in the Long-Term Period After Adult Deceased Donor Liver Transplantation
por: Kim, Jong Man, et al.
Publicado: (2019)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Update on the clinical utility of once-daily tacrolimus in the management of transplantation
por: Posadas Salas, Maria Aurora, et al.
Publicado: (2014)

Update on the clinical utility of once-daily tacrolimus in the management of transplantation
por: Revollo, Jane
Publicado: (2015)

Living donor liver transplantation should be cautiously considered as initial treatment in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection
por: Kim, Jong Man, et al.
Publicado: (2020)

Early disseminated recurrence after liver resection in solitary hepatocellular carcinoma
por: Kim, Jong Man, et al.
Publicado: (2018)

Evaluation of the efficacy and safety of conversion from the tacrolimus capsule to tablet in stable liver transplant recipients with maintenance therapy: a 24-week, open-label, single-center, phase IV exploratory clinical study
por: Kim, Jae-Yoon, et al.
Publicado: (2023)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
por: Pape, Lars, et al.
Publicado: (2011)

Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form
por: Tiankanon, Kanitha, et al.
Publicado: (2022)

Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience
por: Kim, Jong Man, et al.
Publicado: (2018)

Therapeutic drug monitoring of modified release once daily tacrolimus in de novo renal transplant with conversion to a twice daily generic in the stable period
por: Mathew, Binu Susan, et al.
Publicado: (2015)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets
por: Philosophe, Benjamin, et al.
Publicado: (2018)

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
por: Ho, Bing, et al.
Publicado: (2019)

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
por: Kim, Hyeyoung, et al.
Publicado: (2014)

Tacrolimus monotherapy in a patient with lupus flare using once-daily administration protocol
por: Tanaka, Hiroshi, et al.
Publicado: (2011)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Potentially serious medication errors with a new once-daily preparation of tacrolimus (Advagraf™)
por: Saif, Imran, et al.
Publicado: (2009)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients
por: Hurwitz, Jason T, et al.
Publicado: (2021)

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers
por: Zaltzman, Jeffrey S, et al.
Publicado: (2014)

Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
por: Park, Min-Su, et al.
Publicado: (2014)

A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study
por: Dumortier, Jérôme, et al.
Publicado: (2019)

Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study
por: Kim, Jong Man, et al.
Publicado: (2016)

Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
por: Kim, Jong Man, et al.
Publicado: (2016)

Increased survival in hepatitis c patients who underwent living donor liver transplant: a case-control study with propensity score matching
por: Kim, Jong Man, et al.
Publicado: (2017)

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
por: Budde, Klemens, et al.
Publicado: (2022)

Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies
por: Vadcharavivad, Somratai, et al.
Publicado: (2019)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_irgh5n68vgs5b2ep9q7vn9tbos